A National Institutes of Health (NIH)-led clinical trial evaluating hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) has been halted after a data and safety monitoring board determined that the drug was unlikely to benefit hospitalized patients.
The antiviral activity of remdesivir, an investigational treatment for COVID-19, may potentially be reduced if it is coadministered with chloroquine or hydroxychloroquine, according to the FDA.
The FDA has revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate based on emerging data suggesting that these agents are unlikely to be effective against COVID-19.
According to the Food and Drug Administration, the Abbott ID Now™ point-of-care test to diagnose coronavirus disease 2019 (COVID-19) may return false negative results based on early data.
The phase 2b trial is expected to include roughly 2000 participants with confirmed SARS-CoV-2 who are experiencing fever, cough, and/or shortness of breath.
The rituximab biosimilar is now available for use in the treatment of RA and granulomatosis with polyangiitis and microscopic polyangiitis.
The FDA has expanded the approval of Cymbalta to include treatment of fibromyalgia in pediatric patients 13 to 17 years of age.
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
The product that sickened the couple was in powder form and was labeled “for Ornamental Fish Use Only.”
The FDA has issued an Emergency Use Authorization for the Abbott ID Now™ COVID-19 test, a molecular point-of-care test that delivers results within minutes.
